Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
Sina A BeerRobert MöhleGhazaleh TabatabaiDavid A MerleUlrike ErnemannVivien RichterClaudia LengerkePublished in: Bone marrow transplantation (2024)
Primary central nervous system lymphoma (PCNSL) is a potentially curable disease, but affected patients often struggle in everyday life due to disease- and therapy-associated sequelae. High-dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT) is the standard consolidation therapy, replacing whole brain radiation therapy (WBRT) amongst others due to less long-term cognitive decline. Nevertheless, white matter lesions (WML) are common findings in brain MRI after HDC/ASCT, but their clinical significance remains underexplored. Here, we correlate WML and brain atrophy with neuropsychological and quality-of-life evaluations collected post-treatment. We found that a significant part of PNCSL long-term survivors develop a high WML burden after HDC/ASCT, but we fail to associate them with specific patient or therapy characteristics. Intriguingly, even a high WML burden does not seem to affect QoL, basic neurocognition testing or performance status negatively. These results contrast findings in previous neuroimaging studies on healthy and cancer patients.
Keyphrases
- high dose
- stem cell transplantation
- white matter
- cognitive decline
- low dose
- resting state
- radiation therapy
- mild cognitive impairment
- magnetic resonance imaging
- multiple sclerosis
- contrast enhanced
- functional connectivity
- cerebral ischemia
- diffuse large b cell lymphoma
- cell therapy
- end stage renal disease
- locally advanced
- bone marrow
- newly diagnosed
- computed tomography
- stem cells
- platelet rich plasma
- risk factors
- young adults
- chronic kidney disease
- cerebrospinal fluid
- case report
- subarachnoid hemorrhage
- peritoneal dialysis
- case control